HIDROCOL, 4000000 IU/ML SOLUTION FOR USE IN DRINKING WATER/MILK

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

şimdi satın al

Indir Ürün özellikleri (SPC)
11-08-2016

Aktif bileşen:

COLISTIN SULFATE

Mevcut itibaren:

SP Veterinaria, S.A.

ATC kodu:

QA07AA10

INN (International Adı):

COLISTIN SULFATE

Doz:

4000000 IU/ML

Farmasötik formu:

Oral Solution

Reçete türü:

POM

Terapötik grubu:

Bovine, Fowl - Chicken, Fowl - Turkey, Ovine, Porcine

Terapötik alanı:

Colistin

Terapötik endikasyonlar:

Antibiotics

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2016-07-15

Ürün özellikleri

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
HIDROCOL, 4000000 IU/ml solution for use in drinking water/milk
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance:
Colistin (as sulfate)
4000000 IU
Excipients:
Benzyl alcohol
(E1519)
0.010 ml
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Solution for use in drinking water/milk
A brown –orange solution
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (calves), sheep (lambs), pigs, chickens and turkeys.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle (calves), sheep (lambs), pigs, chickens and turkeys:
Treatment and metaphylaxis of enteric infections caused by non-invasive _E. Coli_, susceptible to colistin.
The presence of the disease should be established in the group or herd before metaphylactic treatment.
4.3 CONTRAINDICATIONS
Do not use in horses, particularly in foals, since colistin, due to a shift in the gastrointestinal microflora balance could
lead to the development of antimicrobial associated colitis (Colitis X), typically associated with _Clostridium difficile_,
which may be fatal.
Do not use in case of hypersensitivity to colistin or to any of the excipients.
Do not use in case of resistance to polymyxins.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Colistin exerts concentration-dependent activity against Gram-negative bacteria. Following oral administration high
concentrations are achieved in the gastrointestinal tract, i.e. the target site, due to the poor absorption of the substance.
These factors indicate that a longer duration of treatment than the one indicated in section 4.9, leading to unnecessary
exposure, is not recommended.
As an adjunct to treatment, good management and hygiene practices should be introduced in order to
                                
                                Belgenin tamamını okuyun